NEW YORK, Feb. 27, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Inotek Pharmaceuticals Corporation (“Inotek”) (NASDAQ:ITEK) between July 23, 2015 and December 30, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. To get more information go to:
http://www.zlk.com/pslra/inotek-pharmaceuticals-corporation
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, Inotek misrepresented the efficacy of its drug candidate trabodenoson—the only drug Inotek currently has in its clinical development pipeline—and its attendant capacity to receive New Drug Approval by the U.S. Food and Drug Administration. In particular, it is alleged that the Company made positive statements about the drug despite knowledge that the MATrX-1 phase 3 clinical trial of trabodenoson would fail to meet its primary endpoint of statistical relevance in the reduction of intraocular pressure compared with placebo.
On January 3, 2017, Inotek announced that the Phase 3 trial of trabodenoson had failed to achieve this primary endpoint. Following this news, shares of Inotek fell from a closing price of $6.10 on December 30, 2016, to a closing price of of $1.75 per share on January 3, 2017.
If you suffered a loss in Inotek you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Evernorth Set for Nasdaq Debut With 473 Million XRP Treasury
Malaysia Aviation Group to Buy Airbus SAE Unit
Citi Raises Bitcoin Target to $113,000 as Crypto Outlook Improves
Amazon Eyes $8 Billion Nvidia Chip Spinoff to Fund AI Expansion
MSTR Stock Rises 3% as Strategy Challenges MSCI Bitcoin Stance
Trump Praises Boeing 737 Max After Flydubai Crash Attempt
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal
Nike Stock Slides as Revenue Miss Clouds Turnaround
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin
Flydubai FZ1073 Co-Pilot Accused of Terror Attack
SoftBank Shares Fall After $10 Billion OpenAI Investment
Ripple Locks 700 Million XRP Back in Escrow After October Release
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats
Chainalysis AI Traces $387M Bitget Hack in Under 10 Minutes
California AG Subpoenas OpenAI Over AI Cybersecurity Incidents 



